BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.

Does the MarketBeat Community favor BNTX or GSK?

GSK received 677 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.12% of users gave GSK an outperform vote while only 46.93% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 145 46.93%	Underperform Votes 164 53.07%
GSK	Outperform Votes 822 57.12%	Underperform Votes 617 42.88%

Is BNTX or GSK more profitable?

GSK has a net margin of 8.13% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 48.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
GSK	8.13%	48.59%	11.11%

Is BNTX or GSK a better dividend stock?

BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.7%. GSK pays an annual dividend of $1.57 per share and has a dividend yield of 4.0%. BioNTech pays out -51.0% of its earnings in the form of a dividend. GSK pays out 98.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has more risk and volatility, BNTX or GSK?

BioNTech has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500. Comparatively, GSK has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.

Does the media prefer BNTX or GSK?

In the previous week, GSK had 17 more articles in the media than BioNTech. MarketBeat recorded 41 mentions for GSK and 24 mentions for BioNTech. BioNTech's average media sentiment score of 0.35 beat GSK's score of 0.26 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	8 Very Positive mention(s)	2 Positive mention(s)	9 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
GSK	10 Very Positive mention(s)	2 Positive mention(s)	24 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in BNTX or GSK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate BNTX or GSK?

BioNTech currently has a consensus price target of $143.44, suggesting a potential upside of 55.89%. GSK has a consensus price target of $43.25, suggesting a potential upside of 10.82%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.89
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60

Which has better earnings and valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.75B	8.03	$1.01B	-$3.00	-30.67
GSK	$31.38B	2.57	$3.29B	$1.59	24.55

Summary

GSK beats BioNTech on 14 of the 21 factors compared between the two stocks.